Antibodies with reduced net positive charge

Details Antibodies with reduced net positive charge Antibodies with reduced net positive charge

1997-01-10

1999-11-23

Hutzell, Paula K.

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

5303881, 5303891, 5303913, 5303917, 530402, A61K 39395, C07K 1600

Patent

active

059902868

ABSTRACT:
Modified antibodies which have been by chemical conjugation with agents reactive with free amino groups are disclosed. Among the chemical agents disclosed for use in connection with the invention are heterobifunctional reagents and biotin. The use of these modified antibodies in the diagnosis and therapy of cancer and other mammalian disease is also disclosed. Diagnostic uses include immunoscintography. The modified antibodies may be further conjugated with labels or biologically active molecules for use in diagnosis and therapy. The modified antibodies may also be formulated into pharmaceutical compositions for these purposes.

REFERENCES:
patent: 5021571 (1991-06-01), Mease et al.
Frankel, Arthur E.; Immunotoxins, 1988 Kluwer Academic Publishers; Antibody-toxin conjugation; pp. 213-251.
Orlandi, Rosaria, et al; Hybridoma, vol. 5, No. 1, 1986; Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups; pp. 1-8.
Frankel, Arthur E.; Immuntoxins; 1988; Antibody-toxin conjugation; pp. 213-251.
Khawli, et al.; Antibody, Immunoconjugates, and Radiopharmaceuticals; vol. 6, No. 1, 1993; Improved Immunotargeting of Tumors with Biotinylated Monoclonal Antibodies and Radiolabeled Streptavidin; pp. 13-27.
Najafi, et al.; Nucl.Med.Biol., vol. 19, No. 2, The Evaluation of .sup.186 Re-labeled Antibodies Using N.sub.2 S.sup.4 Chelate In Vitro and In Vivo Using Tumor-bearing Nude Mice; pp. 205-212.
Alauddin, et al.; Antibody, Immunoconjugates, and Radiopharmaceuticals; vol. 4, No. 3, 1991; Evaluation of .sup.99m Tc-Labeled N.sub.2 S.sub.4 Coupled B72.3 and Lym-1 Antibodies as Tumor-Imaging Agents in Tumor-Bearing Nude Mice.
Yazynin, et al., Immunology Letters; 41 (1994) pp. 235-239; Group-selective immunoassay.
Thakur, et al.; The Journal of Nuclear Medicine; vol. 35, No. 5, May 1994; Laboratory Studies; Technetium-99m-Labeled Monoclonal Antibodies: Influence of Technetium-99 Binding Sites; pp. 876-881.
Khawli, et al.; Cancer Biotherapy & Radiopharmaceuticals; vol. 11, No. 3, 1996; Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal Antibodies; pp. 203-215.
Ponomareva et al Immunologiga, 0(4) 1989 pp. 76-78. (Russian) abstract enclosed.

Affiliated with

Also associated with

Rating

Antibodies with reduced net positive charge does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antibodies with reduced net positive charge, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies with reduced net positive charge will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1223258